Answers are grounded in this paper and cite their sources.
Clinical trials demonstrate limited effectiveness of PD-(L)1 inhibitors in prostate cancer, suggesting the need for genomic selection.
Clinical trials with PD-(L)1 inhibitors in patients with prostate cancer administered alone or in combination with other therapies do not appear to have significant benefit in unselected patients, whether part of initial systemic therapy or after the development of hormone resistance. However, there may be benefits in selected tumors harboring mutations with microsatellite instability high/mismatch repair deficiency (MSI-H/dMMR) and, to a lesser extent, high tumor mutational burden (TMB-H). While only a small percentage of prostate tumors have these mutations (MSI-H/dMMR: 3%) and (TMB-H: 4.5%), panel genomic testing can help identify subsets of patient populations who may benefit from PD-(L)1 inhibitors in addition to other molecularly selected agents.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: